GlassScriptPhysician profile
Chester Robbins
NPI 1578554507
$3,872.56
in general payments reported to CMS, 2019-2025
38 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,125 · 2020: $95.57 · 2022: $598 · 2023: $589 · 2024: $976 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,054.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,053.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $580.66 | 2019-2023 | Xarelto |
| Novo Nordisk INC | $375.41 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $318.79 | 2019-2025 | Farxiga, Airsupra, Lokelma |
| Abbvie INC. | $308.10 | 2022-2025 | Vraylar |
| Pfizer INC. | $299.11 | 2019-2025 | |
| Glaxosmithkline, LLC. | $294.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $174.13 | 2019-2024 | |
| Mylan Specialty L.P. | $148.06 | 2020-2024 | Yupelri |
| Lilly USA, LLC | $137.50 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Sunovion Pharmaceuticals INC. | $123.53 | 2019-2022 | |
| Otsuka America Pharmaceutical, INC. | $100.21 | 2023-2025 | Rexulti, Abilify Mycite |
| Novartis Pharmaceuticals Corporation | $92.16 | 2019-2022 | |
| Lundbeck LLC | $90.74 | 2023-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $77.19 | 2024-2025 | Xtampza |
| Bayer Healthcare Pharmaceuticals INC. | $58.98 | 2022-2023 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $57.74 | 2022-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $50.47 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $48.74 | 2022-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $43.94 | 2019-2020 | |
| Neurocrine Biosciences, INC. | $39.50 | 2022 | |
| Ucb, INC. | $38.92 | 2023 | Nayzilam |
| Sumitomo Pharma America, INC. | $36.98 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.02 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $34.55 | 2019 | |
| Seqirus USA INC | $34.28 | 2023 | Fluad Quadrivalent, Flucelvax Quadrivalent |
| Merck Sharp & Dohme LLC | $33.09 | 2024-2025 | Capvaxive, Gardasil 9, Vaxneuvance |
| Inspire Medical Systems, INC. | $31.21 | 2025 | Inspire |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $23.63 | 2024 | Caplyta |
| Amgen INC. | $23.25 | 2024 | Otezla, Repatha |
| Axsome Therapeutics, INC. | $20.49 | 2023 | Auvelity |
| Sanofi Pasteur INC. | $19.54 | 2025 | |
| Kowa Pharmaceuticals America, INC. | $18.72 | 2023 | Seglentis |
| Ibsa Pharma INC. | $18.67 | 2024 | Tirosint, Licart |
| Dexcom, INC. | $17.82 | 2024 | Dexcom G6 Transmitter |
| Aimmune Therapeutics, INC. | $17.75 | 2025 | Vowst |
| Astellas Pharma US INC | $17.39 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $16.50 | 2024 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $14.65 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chester Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.